Conceptually similar, disease modifying therapeutic approach aimed to delay neuronal death in Alzheimer's disease and Parkinson's disease, the most diffuse neurodegenerative conditions among elderly, are directed to the removal of Aβ peptides, hyperphosphorylated tau protein, and α-synuclein (Engelender et al., 2022). This evidence concerns the gene MAPT and Parkinson disease.